Formulation White Papers & Case Studies

1. De-Risk Nucleic Acid Therapeutics Through Strategic Outsourcing 4/20/2026

   Bringing a nucleic acid therapy to market requires specialized formulation and development knowledge. Innovators need rigorous analytical and formulation strategies to achieve stability and quality.

2. Life Cycle Assessment Of Extended Use Strategies For Single-Use Assemblies 4/17/2026

   Examine how extending the use of single‑use assemblies can significantly reduce emissions, resource consumption, and waste in bioprocessing, offering a data‑backed path toward sustainability.

3. Why Flexible, Tailored CDMO Support Is A Non-Negotiable In Sterile Fill-Finish 4/13/2026

   Modern injectable programs require adaptable manufacturing strategies. Learn how flexibility, technical depth, and collaboration reduce complexity, manage change, and protect long‑term supply.

4. Beyond Particle Counting: Why Modern Biologics Need Particle Forensics 4/8/2026

   High particle counts don’t always mean high risk. Identifying particle type and origin—not just quantity—avoids false alarms, protects timelines, and turns data into action.

5. Optimize Time, Space and Cost With Inline Buffer Formulation And System 4/7/2026

   Discover how integrating inline buffer formulation with chromatography reduces buffer waste by 50% and delivers a 710% ROI, transforming downstream efficiency and sustainability.

6. Flexibility In Drug Development: From Tactical Response To Strategic Imperative 4/6/2026

   Build flexibility into your drug development strategy to navigate change effectively, maintain momentum, and drive successful outcomes across every stage of the lifecycle.

7. Early-Phase Injectable Formulation Development 4/6/2026

   Discover how expert-driven strategies and data-centric tools can help you overcome formulation challenges and accelerate the development of stable, high-performance injectable therapeutics.

8. The Effect Of Conventional Cooling Versus Controlled Ice Nucleation On Primary Drying Time 4/1/2026

   See how controlled ice nucleation shortens lyophilization cycles, supports higher drying temperatures, and reduces complexity for amorphous and mixed formulations without sacrificing quality.

9. WuXiHigh 2.0 Delivers A 180 mg/mL Formula 3/26/2026

   This case study shows how smart formulation and integrated development achieved a stable 180 mg/mL biologic for subcutaneous delivery, for teams tackling concentration issues.

10. Tailoring Viral Clearance Study Design 3/4/2026

    Viral‑clearance studies need phase‑appropriate design, strong virus stocks, modality‑specific risk assessment, and alignment with evolving regulations for reliable safety outcomes.